Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$3.02 +7.9%	$2.84	$1.19 ▼ $4.08	$417.61M	1.49	1.37 million shs	1.45 million shs
CYRX CryoPort	$8.97 +5.5%	$7.63	$4.58 ▼ $9.48	$449.10M	1.88	1.11 million shs	441,301 shs
MBX MBX Biosciences	$14.33 +1.3%	$12.51	$4.81 ▼ $27.50	$481.40M	N/A	328,877 shs	280,074 shs
ZOM Zomedica		$0.12	$0.09 ▼ $0.16	$95.35M	1.03	4.72 million shs	790,936 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	0.00%	+1.68%	-4.43%	+44.50%	+153.78%
CYRX CryoPort	0.00%	+4.18%	+12.41%	+48.51%	-1.54%
MBX MBX Biosciences	0.00%	-2.65%	+9.98%	+17.94%	+1,432,999,900.00%
ZOM Zomedica	0.00%	0.00%	0.00%	0.00%	-30.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	2.7565 of 5 stars	3.6	1.0	0.0	0.0	2.1	5.0	0.0
CYRX CryoPort	3.7515 of 5 stars	4.5	1.0	0.0	0.0	2.2	2.5	1.9
MBX MBX Biosciences	1.9633 of 5 stars	3.5	0.0	0.0	0.0	1.1	1.7	0.6
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.10	Buy	$12.89	326.78% Upside
CYRX CryoPort	3.00	Buy	$12.00	33.78% Upside
MBX MBX Biosciences	3.00	Buy	$37.63	162.56% Upside
ZOM Zomedica	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZOM, CYRX, MBX, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
8/6/2025	CYRX CryoPort	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2025	CYRX CryoPort	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$15.00
8/6/2025	CYRX CryoPort	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$16.00
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/22/2025	CYRX CryoPort	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/7/2025	CYRX CryoPort	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $10.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	491.30	N/A	N/A	$0.67 per share	4.51
CYRX CryoPort	$228.38M	1.97	N/A	N/A	$9.53 per share	0.94
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	$25.19M	0.00	N/A	N/A	$0.24 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	11/11/2025 (Estimated)
CYRX CryoPort	-$114.76M	$1.33	6.74	N/A	N/A	37.21%	-9.79%	-5.42%	11/6/2025 (Estimated)
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	-$34.53M	-$0.06	N/A	N/A	N/A	-232.88%	-12.47%	-11.84%	N/A

Latest ZOM, CYRX, MBX, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/5/2025	Q2 2025	CYRX CryoPort	-$0.20	-$0.29	-$0.09	$2.05	$41.74 million	$45.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	7.66	7.66
CYRX CryoPort	0.39	16.24	15.47
MBX MBX Biosciences	N/A	N/A	N/A
ZOM Zomedica	N/A	10.82	10.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
CYRX CryoPort	92.90%
MBX MBX Biosciences	N/A
ZOM Zomedica	8.95%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
CYRX CryoPort	10.00%
MBX MBX Biosciences	52.19%
ZOM Zomedica	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CYRX CryoPort	1,186	50.07 million	45.06 million	Optionable
MBX MBX Biosciences	36	33.59 million	N/A	N/A
ZOM Zomedica	50	979.95 million	938.89 million	Not Optionable

ZOM, CYRX, MBX, and CMPX Headlines

Recent News About These Companies

Zomedica Corp.: Zomedica and VerticalVet Announce Strategic Partnership to Deliver Advanced Veterinary Technologies to Independent Practices

August 19, 2025 | finanznachrichten.de

Zomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary Medicine

August 12, 2025 | finanznachrichten.de

Zomedica Achieves Record Revenue Growth in Q2 2025

August 6, 2025 | msn.com

Non-Pharmacologic Solutions for Pet Dental Health From Prevention to Recovery

July 11, 2025 | dvm360.comD

Zomedica Corp.: Zomedica Announces Strategic PulseVet Shock Wave Partnership with World Equestrian Center - Ocala

July 10, 2025 | finanznachrichten.de

Zomedica Announces Issuance of Additional Patent for its TRUVIEW (R) Microscope - Morningstar

June 25, 2025 | morningstar.comM

Zomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations

May 20, 2025 | finanznachrichten.de

Treat pet pain, inflammation, and anxiety with this high-tech at home therapy

April 24, 2025 | click2houston.comC

Helping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family Members

April 11, 2025 | pix11.comP

Is Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?

March 28, 2025 | insidermonkey.com

15 Cheapest Stocks Insiders Are Buying In March

March 27, 2025 | insidermonkey.com

Earnings call transcript: Zomedica Q4 2024 shows revenue growth

March 15, 2025 | investing.com

Q4 2024 Zomedica Corp Earnings Call

March 15, 2025 | finance.yahoo.com

Zomedica Corp. (ZOMDF) Q4 2024 Earnings Call Transcript

March 13, 2025 | seekingalpha.com

Zomedica (ZOMDF) Gets a Buy from Noble Financial

March 11, 2025 | markets.businessinsider.com

Zomedica Corp.

March 8, 2025 | wsj.com

Zomedica Corp. Announces Transition to OTCQB Venture Market

March 4, 2025 | accessnewswire.comA

NYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)

March 4, 2025 | businesswire.com

Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET

February 26, 2025 | accessnewswire.comA

Zomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

February 12, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZOM, CYRX, MBX, and CMPX Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$3.02 +0.22 (+7.86%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.97 -0.05 (-1.66%)

As of 08/22/2025 07:55 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

CryoPort NASDAQ:CYRX

$8.97 +0.47 (+5.53%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$8.90 -0.07 (-0.78%)

As of 08/22/2025 06:50 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

MBX Biosciences NYSE:MBX

$14.33 +0.18 (+1.27%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$14.34 +0.01 (+0.03%)

As of 08/22/2025 06:52 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time